DefinitionThis section has been translated automatically.
5-HT3 antagonist, antiemetic.
Pharmacodynamics (Effect)This section has been translated automatically.
Selective, competitive binding to 5-HT3 receptors in the brain, among other places. As a result, serotonin can no longer bind to its binding sites, the 5-HT3 receptors, and exert its effect. This directly prevents the development of nausea and vomiting, among other things.
You might also be interested in
IndicationThis section has been translated automatically.
Prophylaxis of cytostatic-induced nausea and vomiting.
Limited indicationThis section has been translated automatically.
Pregnancy, lactation, children < 2 years, hypertension, cirrhosis of the liver, renal failure.
Pregnancy/nursing periodThis section has been translated automatically.
Do not use during pregnancy or lactation (insufficient data available; it is not known whether the active ingredient passes into breast milk).
Dosage and method of useThis section has been translated automatically.
5 mg slowly i.v. or as a short infusion immediately before chemotherapy, afterwards up to 5 days 5 mg/day p.o. For peroral therapy 0.2 ml injection solution/kg bw (= 0.2 mg/kg bw) up to max. 5 ml (1 amp. 5 mg/ml) can be mixed with orange juice or cola and drunk. For the intake of 5 mg/day 1 Kps. p.o. can also be taken.
Undesirable effectsThis section has been translated automatically.
- Cutaneous ADRs: Occasional allergic or anaphylactic reactions. Slight exanthematic skin changes and oedema, especially facial oedema. Local reactions at the infusion site.
- Extracutaneous ADRs: headache, dizziness, hypertension, lymphadenopathy, gastrointestinal disorders (constipation or diarrhea), arthralgia.
InteractionsThis section has been translated automatically.
Phenobarbital, phenytoin and rifampicin lead to a reduction of the tropisetron level.
ContraindicationThis section has been translated automatically.
Use in children, hypersensitivity reactions to other 5-HT3 antagonists.
PreparationsThis section has been translated automatically.
Navoban
Prof. Dr. med. Peter Altmeyer